Perrigo Hopes To Retain Lead From Leiner Woes, Eyes Private Label Zyrtec
This article was originally published in The Tan Sheet
Executive Summary
Prompted by the sudden voluntary suspension of Leiner Health Product's U.S. OTC operations, private labeler Perrigo is looking to maintain its increased market share via key adjustments in its production processes to meet high customer demand
You may also be interested in...
Perrigo Banks On New Products To Continue Market Share Growth
Perrigo got a sales boost in its latest quarter due to Leiner's absence from the U.S. OTC market, but the Allegan, Mich.-based firm looks to new product launches to continue its sales growth as its chief private-label competitor gears up to reenter the market
Perrigo Banks On New Products To Continue Market Share Growth
Perrigo got a sales boost in its latest quarter due to Leiner's absence from the U.S. OTC market, but the Allegan, Mich.-based firm looks to new product launches to continue its sales growth as its chief private-label competitor gears up to reenter the market
Perrigo Banks On New Products To Continue Market Share Growth
Perrigo got a sales boost in its latest quarter due to Leiner's absence from the U.S. OTC market, but the Allegan, Mich.-based firm looks to new product launches to continue its sales growth as its chief private-label competitor gears up to reenter the market